Drugs / rAAV2tYF-CB-hRS1
rAAV2tYF-CB-hRS1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02416622 | May 2015 → Apr 2019 | X-linked retinoschisis | Beacon Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAV2tYF-CB-hRS1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02416622 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “recombinant adeno-associated virus vector expressing retinoschisin” NCT02416622 ↗ |
| Route | Intravitreal | “by intravitreal injection in one eye” NCT02416622 ↗ |